Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation… Read more
Paion AG (PAIOF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.001x
Based on the latest financial reports, Paion AG (PAIOF) has a cash flow conversion efficiency ratio of 0.001x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.94K) by net assets ($-3.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Paion AG - Cash Flow Conversion Efficiency Trend (2003–2022)
This chart illustrates how Paion AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Paion AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paion AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DT REAL ESTATE
MU:DRE2
|
N/A |
|
Nuveen Churchill Direct Lending Corp.
NYSE:NCDL
|
0.028x |
|
KANSAI EL POWER
BE:KPO
|
N/A |
|
Sparindex INDEX EmMarkBoLokval
CO:SPVIEMMBLV
|
N/A |
|
RHOEN-KLINIKUM - Dusseldorf Stock Exchang
DU:RHK
|
0.008x |
|
CGRE AG
F:CGX
|
N/A |
|
SHENANDOAH TELE (SH9.SG)
STU:SH9
|
0.024x |
|
Insimbi Refractory Alloy Supply
JSE:ISB
|
0.001x |
Annual Cash Flow Conversion Efficiency for Paion AG (2003–2022)
The table below shows the annual cash flow conversion efficiency of Paion AG from 2003 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $6.62 Million | $5.94 Million | 0.898x | +129.68% |
| 2021-12-31 | $7.00 Million | $-21.18 Million | -3.026x | -7209.48% |
| 2020-12-31 | $21.29 Million | $906.13K | 0.043x | +122.03% |
| 2019-12-31 | $14.73 Million | $-2.85 Million | -0.193x | +68.60% |
| 2018-12-31 | $20.82 Million | $-12.81 Million | -0.615x | +12.39% |
| 2017-12-31 | $25.23 Million | $-17.72 Million | -0.702x | -51.21% |
| 2016-12-31 | $24.94 Million | $-11.59 Million | -0.465x | +37.16% |
| 2015-12-31 | $35.56 Million | $-26.29 Million | -0.739x | -284.24% |
| 2014-12-31 | $62.61 Million | $-12.04 Million | -0.192x | -46.89% |
| 2013-12-31 | $13.33 Million | $-1.75 Million | -0.131x | -113.18% |
| 2012-12-31 | $15.57 Million | $15.48 Million | 0.994x | -93.74% |
| 2011-12-31 | $-463.67K | $-7.36 Million | 15.869x | +2432.23% |
| 2010-12-31 | $11.97 Million | $-8.14 Million | -0.680x | -5.02% |
| 2009-12-31 | $19.30 Million | $-12.51 Million | -0.648x | -345.11% |
| 2008-12-31 | $31.53 Million | $-4.59 Million | -0.146x | +52.37% |
| 2007-12-31 | $43.05 Million | $-13.16 Million | -0.306x | -330.49% |
| 2005-12-31 | $52.75 Million | $-3.74 Million | -0.071x | -121.75% |
| 2004-12-31 | $15.31 Million | $5.00 Million | 0.326x | +125.86% |
| 2003-12-31 | $7.58 Million | $-9.57 Million | -1.262x | -- |